

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Leah E. Appel, et al. :
APPLICATION NO.: To Be Assigned : Examiner: To Be Assigned
FILING DATE: To Be Assigned : Group Art Unit: To Be Assigned
TITLE: Controlled Release By Extrusion of Solid :
Amorphous Dispersions of Drugs

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: MARCH 11, 2004

James T. Jones
James T. Jones
Attorney for Applicant(s)
Reg. No. 30,561

Pfizer Inc.
Patent Department, Box 8260-1611
Eastern Point Road
Groton, CT 06340
(860) 441-4903

EXPRESS MAIL NO. EV 271824862 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Leah E. Appel, et al. :

Examiner: To Be Assigned

APPLICATION NO.: To Be Assigned :

FILING DATE: To Be Assigned

:Group Art Unit: To Be Assigned

TITLE: Controlled Release By Extrusion of Solid :
Amorphous Dispersions of Drugs

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: MARCH 11, 2004

James T. Jones
James T. Jones
Attorney for Applicant(s)
Reg. No. 30,561

Pfizer Inc.
Patent Department, Box 8260-1611
Eastern Point Road
Groton, CT 06340
(860) 441-4903

EXPRESS MAIL NO. EV 271824862 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Leah E. Appel, et al.

Examiner: To Be Assigned

APPLICATION NO.: To Be Assigned

FILING DATE: To Be Assigned

Group Art Unit: To Be Assigned

TITLE: Controlled Release By Extrusion of Solid
Amorphous Dispersions of Drugs

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: MARCH 11, 2004

James T. Jones
James T. Jones
Attorney for Applicant(s)
Reg. No. 30,561

Pfizer Inc.
Patent Department, Box 8260-1611
Eastern Point Road
Groton, CT 06340
(860) 441-4903

EXPRESS MAIL NO. 9U 271824862 US

| | | | | | | | | | | | | | | |
|--|--|--|--|--|--|--|--|--|-------------------------------------|--|--|----------------------------------|--|--|
| INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i> | | | | | | | | | ATTY. DOCKET NO. PC10270BJTJ | | | SERIAL NO. To Be Assigned | | |
| APPLICANT Leah E. Appel, et al. | | | | | | | | | FILING DATE Herewith | | | GROUP To Be Assigned | | |

| U.S. PATENT DOCUMENTS | | | | | | | | | | | | | |
|------------------------------|--|-----------------|---|---|---|---|---|---|------------|-----------------|-------|----------|-------------------------------|
| EXAMINER INITIAL | | DOCUMENT NUMBER | | | | | | | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
| | | 5 | 7 | 3 | 6 | 1 | 5 | 9 | 7 April 98 | Chen et al | 424 | 480 | |
| | | 5 | 5 | 1 | 6 | 5 | 2 | 7 | 14 May 96 | Curatolo | 424 | 461 | |
| | | 4 | 8 | 5 | 1 | 2 | 3 | 2 | 25 July 89 | Urquhart et al | 424 | 469 | |
| | | 4 | 6 | 2 | 4 | 8 | 4 | 8 | 25 Nov 86 | Lee | 424 | 22 | |
| | | 4 | 6 | 1 | 2 | 0 | 0 | 8 | 16 Sept 86 | Wong et al | 604 | 892 | |
| | | 4 | 3 | 2 | 7 | 7 | 2 | 5 | 4 May 82 | Cortese et al | 128 | 260 | |
| | | 5 | 4 | 5 | 6 | 9 | 2 | 3 | 10 Oct 95 | Nakamichi et al | 424 | 489 | |
| | | 4 | 9 | 8 | 3 | 5 | 9 | 3 | 8 Jan 91 | Miyajima et al | 514 | 110 | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | | | | | | | | |
|---------------------------------|----|---|---|---|---|---|---|---|------------|---------------|-------|----------|-------------|----|
| DOCUMENT NUMBER | | | | | | | | | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
| | | | | | | | | | | | | | YES | NO |
| | CA | 1 | 3 | 3 | 0 | 8 | 8 | 6 | | Canadian | A01N | 25/08 | | |
| | WO | 9 | 7 | 0 | 2 | 0 | 1 | 7 | 23 Jan 97 | International | A61K | 9/14 | | |
| | WO | 9 | 3 | 1 | 1 | 7 | 4 | 9 | 24 June 93 | International | A61K | 9/10 | | |
| | EP | 0 | 5 | 5 | 2 | 7 | 0 | 8 | 28 July 93 | EPO | A61K | 9/14 | | |
| | | | | | | | | | | | | | | |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | |
|---|--|--|
| | | James L. Ford, The Current Status of Solid Dispersions, 61 Pharm. Acta Helv. 69-88, 1986 |
| | | Chowdary et al, 32 Indian Drugs 477-483, 1995 |
| | | Dangprasirt et al., 21 Drug Development & Ind. Pharm. 2323, 1995 |
| | | Goracinova et al., 22 Drug Development & Ind. Pharm. 255, 1996 |
| | | |

| | |
|---|------------------------|
| EXAMINER | DATE CONSIDERED |
| <small>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small> | |

EXPRESS MAIL NO. 90271824862US